ERRATUM

A prospective randomized trial of the optimal dose of mannitol for intraoperative brain relaxation in patients undergoing craniotomy for supratentorial brain tumor resection

TO THE READERSHIP: An error appeared in the article by Seo et al. (Seo H, Kim E, Jung H, et al: A prospective randomized trial of the optimal dose of mannitol for intraoperative brain relaxation in patients undergoing craniotomy for supratentorial brain tumor resection. *J Neurosurg* 126:1839–1846, 2017).

Several ratios were incorrectly calculated in Tables 1 and 2. The ratios should be 2 (6.5%), 3 (9.7%), and 6 (19.4%)—not 2 (6.4%), 3 (9.6%), and 6 (19.2%). The updated tables are shown here.

The article has been corrected online as of June 1, 2018.

Hee-Pyoung Park, MD, PhD

Seoul National University College of Medicine, Bundang-gu, Seongnam, Korea

INCLUDE WHEN CITING

Published online June 1, 2018; DOI: 10.3171/2018.1.JNS16537a.

©AANS 2018, except where prohibited by US copyright law

TABLE 1. Demographics in the 124 patients included in this study

Variables	Group A (n = 31)	Group B (n = 31)	Group C (n = 31)	Group D (n = 31)	p Value
Mean age in yrs (range)	52.5 (32–74)	53.1 (28–78)	52.1 (23–79)	48.9 (24–76)	0.474
Male sex	20 (64.5%)	15 (48.4%)	12 (38.7%)	14 (45.2%)	0.214
Mean height, cm	165.5 (9.4)	162.7 (8.9)	162.4 (7.9)	163.2 (9.5)	0.508
Mean weight, kg	65.0 (10.0)	65.7 (12.8)	63.6 (10.0)	64.0 (13.0)	0.723
Mean BMI, kg/m ²	23.5 (2.5)	24.9 (4.4)	23.9 (3.9)	23.9 (3.9)	0.447
Tumor type					0.868
Anaplastic astrocytoma	0 (0%)	2 (6.5%)	1 (3.2%)	4 (12.9%)	
Glioblastoma	5 (16.1%)	6 (19.4%)	5 (16.1%)	6 (19.4%)	
Oligodendroglioma	1 (3.2%)	3 (9.7%)	2 (6.5%)	1 (3.2%)	
Other glioma	3 (9.7%)	3 (9.7%)	1 (3.2%)	3 (9.7%)	
Meningioma	16 (51.6%)	10 (32.2%)	14 (45.2%)	12 (38.7%)	
Metastasis	3 (9.7%)	5 (16.1%)	4 (12.9%)	2 (6.5%)	
Other	3 (9.7%)	2 (6.5%)	4 (12.9%)	3 (9.7%)	
Tumor location					0.932
Frontal	21 (67.7%)	16 (51.6%)	16 (51.6%)	18 (58.1%)	
Temporal	4 (12.9%)	4 (12.9%)	6 (19.4%)	3 (9.7%)	
Parietal	2 (6.5%)	5 (16.1%)	4 (12.9%)	4 (12.9%)	
Occipital	1 (3.2%)	1 (3.2%)	2 (6.5%)	2 (6.5%)	
Sphenoidal	1 (3.2%)	3 (9.7%)	1 (3.2%)	1 (3.2%)	
Other	2 (6.5%)	2 (6.5%)	2 (6.5%)	3 (9.7%)	
Mean max tumor diameter, mm	50.6 (14.4)	45.5 (15.4)	50.0 (16.2)	50.7 (11.8)	0.476
Mean midline shift, mm	9.2 (4.3)	10.0 (6.7)	8.4 (5.9)	9.0 (4.0)	0.695
Peritumoral edema >10 mm	24 (77.4%)	25 (80.6%)	25 (80.6%)	27 (87.1%)	0.879

The administered dose of mannitol is 0.25 g/kg in Group A, 0.5 g/kg in Group B, 1.0 g/kg in Group C, and 1.5 g/kg in Group D. Values are presented as the number of patients (%) unless indicated otherwise. Mean values are presented as the mean (SD) unless indicated otherwise.

TABLE 2. Intraoperative data and postoperative outcomes

Variables	Group A (n = 31)	Group B (n = 31)	Group C (n = 31)	Group D (n = 31)
Intraop data				
Mean time to assess brain relaxation from end of mannitol administration, mins	33 (5)	32 (6)	32 (5)	35 (6)
Median op time, mins	269 [199–341]	258 [239–377]	263 [235–349]	323 [235–391]
Median anesthesia time, mins	330 [294–415]	330 [320–458]	340 [305–420]	390 [300–474]
Median administered fluids, ml	2250 [1575–2825]	1800 [1700–2400]	2300 [1500–2850]	2225 [1575–2913]
Median total urine output, ml	1540 [725–1908]	1145 [910–1545]	1500 [1180–2500]†	2195 [1394–3005]†,‡
Median total estimated blood loss, ml	600 [300–800]	540 [288–850]	500 [350–700]	650 [400–1100]
Median total fluid balance, ml	520 [28–912]	330 [–40 to 833]	–70 [–300 to 945]	–175 [–670 to 620]**
Median serum osmolality after mannitol administration, mOsm/kg				
At T1	299 [295–302]	298 [295–304]	295 [291–300]	299 [291–303]
At T2	303 [301–309]	303 [300–307]	306 [303–310]†	315 [310–317]*,†,‡
At T3	303 [299–308]	303 [299–306]	306 [302–310]††	312 [309–314]*,†,‡
At T4	303 [300–306]	299 [295–307]	305 [299–309]	307 [304–313]**,††,‡‡
Additional methods for brain relaxation				
Overall	6 (19.4%)	7 (22.6%)	3 (9.7%)	2 (6.5%)
Additional mannitol administration	4 (12.9%)	0 (0%)	0 (0%)	0 (0%)
Transient hyperventilation	1 (3.2%)	2 (6.5%)	2 (6.5%)	2 (6.5%)
Transient hyperventilation + additional mannitol administration	1 (3.2%)	4 (12.9%)	1 (3.2%)	0 (0%)
Reverse Trendelenburg position	0 (0%)	1 (3.2%)	0 (0%)	0 (0%)
Postop outcome				
Median ICU stay, days	2 [2–3]	2 [2–3]	2 [2–4]	3 [2–5]
Median hospital stay, days	9 [8–13]	9 [8–13]	12 [9–16]	11 [8–20]

T1 = just before the mannitol administration; T2 = 30 minutes after the end of mannitol administration; T3 = 60 minutes after the end of mannitol administration; T4 = 180 minutes after the end of mannitol administration.

Values are presented as the number of patients (%) unless indicated otherwise. Mean values are presented as the mean (SD). Median values are presented as the median [IQR].

*p < 0.01, compared with Group A; **p < 0.05, compared with Group A; †p < 0.01, compared with Group B; ††p < 0.05, compared with Group B; ‡p < 0.01, compared with Group C; ‡‡p < 0.05, compared with Group C.